Skip to content
OpenCapital
Get started

West Pharmaceutical Services WST Proprietary Products — Operating Income (Loss)

Other segment segments

West Vantage
$15.6M—

Similar metrics at other companies

TGE
TGENProducts Segment — Operating Income (Loss)
-$254.97K-154%
VHI
VHIComponent Products — Operating Income
$7.1M+20.3%
Stepan logo
SCLSpecialty Products — Operating Income
$4.72M-14.4%
MML
MMLPSpecialty Products — Operating Income (Loss)
$3.53M-5.7%
Balchem logo
BCPCSpecialty Products — Operating Income (Loss)
$11.94M+24.5%
AstroNova, Inc. logo
ALOTProduct Identification — Operating Income
$566K+118%

Other financials

Income statement

See full
Revenue$844.9M+21.0%
Gross profit$296.4M+27.8%
Operating income$177.1M+65.5%
Net income$138.8M+54.6%
EPS (diluted)$1.92+56.1%

Balance sheet

See full
Cash & equivalents$521.4M+29.0%
Total debt$321.0M+4.4%
Total equity$3.0B+11.5%
Total assets$4.1B+13.6%

Cash flow

See full
Operating cash flow$89.9M-30.5%
CapEx$42.7M-40.1%
Free cash flow$47.2M-18.8%

Valuation

See full
Market cap$25.36B+64.2%
Enterprise value$25.16B+65.1%
P/E46.7×+15.1×
P/S7.9×+2.7×

Profitability

See full
Gross margin36.3%+1.7pp
Operating margin20.3%+1.2pp
Net margin16.8%+0.7pp
FCF margin14.2%+3.6pp

Returns & leverage

See full
Return on equity19.1%+1.7pp
Debt / equity0.1×0.0×
Current ratio2.7×-0.1×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: West Pharmaceutical Services’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about West Pharmaceutical Services's proprietary products — operating income (loss).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is West Pharmaceutical Services's proprietary products — operating income (loss)?
West Pharmaceutical Services (WST) reported proprietary products — operating income (loss) of $189.2M in Q1 2026.
How has West Pharmaceutical Services's proprietary products — operating income (loss) changed year-over-year?
West Pharmaceutical Services's proprietary products — operating income (loss) increased by 44.9% year-over-year, from $130.6M to $189.2M.
What is the long-term trend for West Pharmaceutical Services's proprietary products — operating income (loss)?
Over 2 years (2023 to 2025), West Pharmaceutical Services's proprietary products — operating income (loss) has grown at a -3.8% compound annual growth rate (CAGR), from $710.1M to $657.2M.
What does proprietary products — operating income (loss) mean?
This is the profit generated from the proprietary products segment after deducting all operating expenses from net sales. It serves as the primary measure of the segment's core operational profitability and financial health.